Related Experiment Videos
Paroxysmal supraventricular tachycardia in the infant
American Family Physician
|September 1, 1980
Summary
Paroxysmal supraventricular tachycardia (PSVT) is increasingly detected in newborns. While tolerated in fetuses, PSVT in infants can cause heart failure, with digoxin being the preferred treatment.
Area of Science:
- Neonatal cardiology
- Fetal medicine
- Pediatric electrophysiology
Background:
- Paroxysmal supraventricular tachycardia (PSVT) detection has increased in fetuses and newborns with advanced monitoring.
- Fetal PSVT is generally well-tolerated, but neonatal PSVT can precipitate congestive heart failure.
Purpose of the Study:
- To review the clinical presentation and management of paroxysmal supraventricular tachycardia in the neonatal population.
- To highlight the association between Wolff-Parkinson-White syndrome and PSVT.
- To identify optimal therapeutic strategies for infant PSVT.
Main Methods:
- Literature review of studies on fetal and neonatal tachyarrhythmias.
- Analysis of clinical outcomes and treatment responses.
- Focus on the role of Wolff-Parkinson-White syndrome.
Main Results:
- PSVT is more frequently identified in neonates due to improved monitoring.
- Untreated PSVT in newborns and infants poses a risk of developing congestive heart failure.
- Wolff-Parkinson-White syndrome is a common comorbidity.
Conclusions:
- Early recognition and management of PSVT in neonates are crucial to prevent adverse cardiac events.
- Digoxin is established as the primary pharmacologic agent for treating PSVT in infants.
- Understanding the link with Wolff-Parkinson-White syndrome informs treatment decisions.